Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.
Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, Olofsson B, Probstfield J, McMurray JV; Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Yusuf S, et al. Among authors: gerstein hc. Circulation. 2005 Jul 5;112(1):48-53. doi: 10.1161/CIRCULATIONAHA.104.528166. Epub 2005 Jun 27. Circulation. 2005. PMID: 15983242 Clinical Trial.
Effect of ramipril on the incidence of diabetes.
DREAM Trial Investigators; Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR. DREAM Trial Investigators, et al. Among authors: gerstein hc. N Engl J Med. 2006 Oct 12;355(15):1551-62. doi: 10.1056/NEJMoa065061. Epub 2006 Sep 15. N Engl J Med. 2006. PMID: 16980380 Free article. Clinical Trial.
The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.
Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B, Pfeffer MA, Yusuf S; CHARM Program Investigators. Gerstein HC, et al. Arch Intern Med. 2008 Aug 11;168(15):1699-704. doi: 10.1001/archinte.168.15.1699. Arch Intern Med. 2008. PMID: 18695086 Clinical Trial.
Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program.
Preiss D, Zetterstrand S, McMurray JJ, Ostergren J, Michelson EL, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, Gerstein HC, Sattar N; Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Investigators. Preiss D, et al. Among authors: gerstein hc. Diabetes Care. 2009 May;32(5):915-20. doi: 10.2337/dc08-1709. Epub 2009 Feb 5. Diabetes Care. 2009. PMID: 19196892 Free PMC article.
Albuminuria in chronic heart failure: prevalence and prognostic importance.
Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ; CHARM Investigators and Committees. Jackson CE, et al. Among authors: gerstein hc. Lancet. 2009 Aug 15;374(9689):543-50. doi: 10.1016/S0140-6736(09)61378-7. Lancet. 2009. PMID: 19683640
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
Holman RR, Bethel MA, Chan JC, Chiasson JL, Doran Z, Ge J, Gerstein H, Huo Y, McMurray JJ, Ryden L, Liyanage W, Schröder S, Tendera M, Theodorakis MJ, Tuomilehto J, Yang W, Hu D, Pan C; ACE Study Group. Holman RR, et al. Am Heart J. 2014 Jul;168(1):23-9.e2. doi: 10.1016/j.ahj.2014.03.021. Epub 2014 Apr 5. Am Heart J. 2014. PMID: 24952856 Clinical Trial.
435 results